Uncategorized

First to File. First to Profit: The Complete Guide to Paragraph IV Certifications and 180-Day Exclusivity

First-to-File, First-to-Profit: The Quiet Power of Paragraph IV and 180-Day Exclusivity
In generic drug competition, speed isn’t just a competitive advantage—it can be a business model.
A lot of people talk about “patent challenges” like they’re purely…

First to File. First to Profit: The Complete Guide to Paragraph IV Certifications and 180-Day Exclusivity Read Post »

Uncategorized

Read Their Drug Pipeline Before They Publish It: Competitive Forecasting with Pharmaceutical Patent Intelligence

Before a drug ever hits a press release, the real competition is already in motion.
Most teams only react once a pipeline is public—when a company files a press release, posts trial results, or publishes a slide deck. But in pharma, “public” is often…

Read Their Drug Pipeline Before They Publish It: Competitive Forecasting with Pharmaceutical Patent Intelligence Read Post »

Uncategorized

Pick the Right Patent Or Leave Billions on the Table: The Definitive Guide to the One-Patent-Per-Product Rule and PTE Selection Strategy

Pick the Right Patent—or Leave Billions on the Table: The One-Patent-Per-Product Rule and PTE Selection Strategy
In pharma, the difference between winning and losing often isn’t science—it’s paperwork, timing, and precision.
A single misstep in patent …

Pick the Right Patent Or Leave Billions on the Table: The Definitive Guide to the One-Patent-Per-Product Rule and PTE Selection Strategy Read Post »

Biotechblog
Scroll to Top